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rapamycin (mTOR), inhibited hepatic lipogenic enzymes, and reduced hepatic triglyceride content.
However, BCAA caused signiﬁcant hepatic damage in HFDmice, evidenced by exacerbated hepatic oxida-
tive stress, increased hepatic apoptosis, and elevated circulation hepatic enzymes. Compared to solely
HFD-fed animals, plasma levels of free fatty acids (FFA) in the HFD+ BCAA group are signiﬁcantly further
increased, due largely to AMPKα2-mediated adipocyte lipolysis. Lipolysis inhibition normalized plasma
FFA levels, and improved insulin sensitivity. Surprisingly, blocking lipolysis failed to abolish BCAA-
induced liver injury. Mechanistically, hepatic mTOR activation by BCAA inhibited lipid-induced hepatic
autophagy, increased hepatic apoptosis, blocked hepatic FFA/triglyceride conversion, and increased he-
patocyte susceptibility to FFA-mediated lipotoxicity. These data demonstrated that BCAA reduces HFD-
induced body weight, at the expense of abnormal lipolysis and hyperlipidemia, causing hepatic
lipotoxicity. Furthermore, BCAA directly exacerbate hepatic lipotoxicity by reducing lipogenesis and
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With the prevalence of obesity, non-alcoholic fatty liver disease
(NAFLD) has become the most common chronic liver disease in the
world (Angulo, 2002). Although most patients are asymptomatic,
NAFLDmay progress to non-alcoholic steatohepatitis (NASH), a predis-
posing condition of liver cirrhosis, end-stage liver disease, and hepato-
cellular carcinoma (Angulo, 2002). Unfortunately, as there are no
speciﬁc and effective therapies for NASH, both better understanding of
the molecular mechanisms underlying NAFLD and efﬁcacious therapies
are in great need.
Excessive carbohydrate intake is causatively linked to obesity/diabe-
tes. Low-carbohydrate, high-fat/high protein diets like Atkins diet are
often recommended to the obesity patients to promote weight loss
(Astrup et al., 2004). More importantly, typical western meat-rich
foods contain both high protein and high fat (Heidemann et al., 2008;
Cordain et al., 2005). Although the hazardous effect of high fat upon he-
patic structure/function is well-recognized, the impact of concomitant
high protein intake upon HF-induced liver injury remains unclear (de
Wit et al., 2012). Branched chain amino acids (BCAA, including leucine,
isoleucine, and valine) are a group of essential amino acids. Relatively
abundant in food, they account for 20% of total protein intake (Harris
et al., 2005). Part of the high-protein diet often recommended for
obese patients, BCAA intake reduces body weight (Hutson et al.,
2005). However, recent studies demonstrate elevated circulating
BCAA are strongly associated with NAFLD-related metabolic disorders,
such as obesity, metabolic syndrome, and type 2 diabetes mellitus
(Lynch and Adams, 2014). Moreover, as opposed to patients with sim-
ple fatty liver, hepatic BCAA accumulation is a signaturemetabolic ﬁnd-
ing in patients with steatohepatitis (Lake et al., 2015). Finally,
downregulated expression of hepatic BCAA-degrading enzymes is also
a hallmark of non-alcoholic fatty liver (Lake et al., 2015; Mardinoglu
et al., 2014). Together, these clinical studies strongly suggest BCAA in-
take may have negative impact upon liver structure/function, particu-
larly in obesity. Mechanisms responsible for this quandary (how BCAA
induces weight-loss but damages the liver) remain unknown. More-
over, whether elevated circulatory BCAA plays a causative role in the
liver injury observed in NAFLD patients has not been determined.
Emerging evidence demonstrates free fatty acids (FFA) and their
metabolites play a critical role in the pathogenesis of NASH
(Neuschwander-Tetri, 2010). Excess hepatic FFA accumulation results
in increased oxidative stress, lipid peroxidation, and hepatocellular ap-
optosis, leading to NASH development (Fuchs and Sanyal, 2012).
These FFA-mediated hepatotoxic effects are termed hepatic lipotoxicity.
Uptake from adipocyte-released FFA in circulation and de novo synthe-
sis by hepatocytes are the two most signiﬁcant sources of hepatic FFA
(Fuchs and Sanyal, 2012). As such, adipocyte lipolysis inhibition and he-
patic lipogenic suppression are effective interventions attenuating he-
patic FFA accumulation and resultant liver injury. The effect of BCAA
supplementation upon adipocyte lipolysis, hepatic lipogenesis, and ulti-
mately hepatic FFA accumulation (particularly during obesity or diabe-
tes) remains unknown.
Utilizing high-fat-diet (HFD) and HFD + BCAA models, the current
study has three speciﬁc aims: 1) to determine whether BCAA contrib-
utes to or protects against HF-induced liver injury; 2) to determine
whether BCAA may have direct negative impact upon liver structure/
function in HFD-induced obese animals; and 3) if so, clarify the respon-
sible underlying molecular mechanisms.
2. Methods and Materials
2.1. Animals, Diets, and Treatments
All study protocolswere approved by the Animal Care andUse Com-
mittee of the Fourth Military Medical University, and strictly followed
guidelines regarding the humane use and care of laboratory animalsfor biomedical research published by the National Institutes of Health
(No. 85-23, revised 1996). Adult male wild-type C57BL6J mice (aged
from 8 to 10 weeks) and green ﬂuorescent protein-light chain-3 (GFP-
LC3) transgenic C57BL6J mice (aged from 8 to 10 weeks) were pur-
chased from the Vital River Company, China. There was no statistically
difference in the animal age between respective groups. During the
study duration, animals were maintained in a temperature-controlled
barrier facility at 26 °C with a 12 hour-light/dark cycle. Both wild-type
and GFP-LC3 transgenic mice were randomly divided into four groups:
normal diet (ND) group, ND + BCAA group, high fat diet (HFD) group,
and the HFD + BCAA group. The HFD (60% of kcal fat, D12492) and
ND (10% of kcal fat, D12450) were purchased from Research Diets Inc.
(USA). The BCAA mixture (L-leucine 25 g, L-isoleucine 12.5 g, and L-
valine 12.5 g) was added into 1 L drinkingwater. All themice had unre-
stricted access to food and water. These diets were fed for 12 weeks.
During this period, food and water intake were monitored bi-weekly.
Acipimox (10mg/kg bodyweight, Selleck Inc., China) was administered
daily by intraperitoneal (IP) injection. Rapamycin (1 mg/kg body
weight, Selleck Inc., China)was given IP every other day. After overnight
fasting (from 9 pm to 9 am next morning), animals were anesthetized
with 2% isoﬂurane inhalation and sacriﬁced by cutting the carotid ar-
tery. After animal sacriﬁce, the blood, epididymal white fat, liver, and
gastrocnemiusmuscle were collected and used for the following biolog-
ical analyses.
2.2. In Vitro and In Vivo Lipolysis Assay
In cultured 3T3-L1 cell-derived adipocytes, the lipolysis assay was
performed as previously described (Wu et al., 2015). Brieﬂy, adipocytes
were incubated andwere treatedwith orwithout insulin (10 ng/ml) for
10 min, followed by 90 min of stimulation with 10 μM isoproterenol
(ISO). Subsequently, 1 ml of the incubation medium of adipocytes was
removed and acidiﬁedwith 100 μl 30% trichloroacetic acid. Themixture
was carefully vortexed and was centrifuged at 3000g for 10 min at 4 °C.
100 μl supernatant was collected and was neutralized with 10 μl 10%
KOH, and tested for glycerol concentration (nM glycerol released per
mg protein) via commercial glycerol assay kit (Biovision, USA). For
in vivo lipolysis, mice were fasted for 3 h and subjected to speciﬁc β3-
adrenergic receptor agonist CL-316243 (0.1 mg/kg body weight,
Sigma, US) IP 5min after insulin (0.75 IU/kg bodyweight, NovoNordisk,
Sweden) or saline injection. Blood sampleswere obtained via tail vein 0,
30, 60, and 120 min after CL-316243 injection to determine FFA and
glycerol levels.
2.3. GFP-LC3 Droplets Detection
After 12week-diet intervention,maleGFP-LC3 transgenicmicewere
sacriﬁced. Livers were harvested. Frozen hepatic sections were pre-
pared, and subjected to confocal microscopy (Olympus, Japan) at
588 nm by argon laser at b2% of full power, described previously in de-
tail (Kim and Lemasters, 2011). All images were captured and were an-
alyzed via Image-Plus software.
2.4. Leucine Tolerance Test
As described by Lu et al., brieﬂy, overnight fastedmicewere subject-
ed to IP leucine solution (150mM, dosed 15 μl/g bodyweight) (Lu et al.,
2009). Blood samples were obtained via tail vein 0, 1, 2, and 4 h after
leucine administration. Plasma BCAA levels were measured.
2.5. Lean and Fat Mass Calculation
The body fat mass was calculated as previously described (D'Antona
et al., 2010). Brieﬂy, the total epididymal, perirenal,mesentery, and sub-
cutaneous fat pads were carefully dissected, collected, and weighted.
The lean body mass equals body weight minus body fat mass.
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Branched-chain α-ketoacid dehydrogenase (BCKD) complex actual
activity wasmeasured by spectrophotometric assay, as described in de-
tail previously (Lian et al., 2015). Brieﬂy, BCKD complex was isolated
from tissue extracts using 9% polyethylene glycol. BCKD enzyme activity
was determined spectrophotometrically bymeasuring the rate of NADH
production resulting from the conversion of α-keto-isovalerate into
isobutyryl-CoA. A unit of enzyme activity was deﬁned as 1 μmol NADH
formation per minute at 37 °C.
2.7. Statistical Analyses
All data are presented asmean+ standard error of themean (SEM).
The student's t-test with a two-tail distribution tested statistical signiﬁ-
cance for two groups. For more than two groups, two-way ANOVA
followed by post-hoc analysis was performed for analyzing two param-
eters. GraphPad Prism software was utilized. P values b 0.05 were con-
sidered statistically signiﬁcant.
A further description of employed materials and methods is provid-
ed in “Supplementary Materials”.
3. Results
3.1. BCAA Supplementation in HFD-Induced Obesity/DiabeticMice Reduced
Fat Mass and Body Weight, and Suppressed Hepatic De Novo Lipogenesis
The catabolismof BCAA is tightly regulated in vivo by the BCKD com-
plex (Harris et al., 2005). In normal diet (ND) mice, plasma levels ofFig. 1.BCAA supplementation reduced fatmass and bodyweight gain inHFD-induced obese/dia
fat diet (HFD). (A) Plasma BCAA was determined via commercial kit and plasma BCKA was de
results in ND and HFD mice. (C to F) ND and HFD-fed mice were then orally administered BC
plasma BCAA. (D) Body weight was determined every two weeks. (E) Lean and fat mass, and
versus HFD. Data presented as mean + SEM.BCAA and its downstream metabolite BCKA were low, as dietary BCAA
was rapidly degraded as determined by leucine tolerance test
(Fig. 1A–C). However, in high-fat diet (HFD)-induced obese mice, plas-
ma BCAA and BCKA levels were signiﬁcantly elevated (Fig. 1A and B).
The leucine tolerance test consistently demonstrated that BCAA clear-
ance capacity was signiﬁcantly impaired in HFD-fed mice (Fig. 1B)
which might be a main contributor to increased BCAA accumulation in
HFD-induced obesity/diabetic mice. BCAA administration signiﬁcantly
increased daily consumptions of leucine, isoleucine, and valine (Supple-
mentary Table 3). BCAA supplementation had no signiﬁcant effect upon
plasma BCAA in NDmice. However, supplementation of BCAA atop HFD
signiﬁcantly further increased plasma BCAA levels, including leucine/
isoleucine and valine (Fig. 1C and Supplementary Fig. 3). Mechanistical-
ly, adipose and liver BCKD complex activity (the rate-limiting enzyme
catalyzing BCAA catabolism) is signiﬁcantly decreased (see Supplemen-
tary Fig. 1A and B) due to increased phosphorylation of the BCKD E1α
subunit at serine293 (Lu et al., 2009) inHFD animals (see Supplementary
Fig. 1D and E). However, HFD had no signiﬁcant effect upon BCKD phos-
phorylation or activity in skeletal muscle (see Supplementary Fig. 1C
and F). Taken together, these data indicated that HFD inhibited BCAA ca-
tabolism in the liver and adipose tissue, increased circulating BCAA
abundance, and further exacerbated BCAA accumulation when BCAA
was supplemented atop HFD.
Because BCAA supplementation alone (ND + BCAA) had no signiﬁ-
cant effect upon plasma BCAA levels (Fig. 1C) and, more importantly,
long-term BCAA supplementation alone have no signiﬁcant effects on
metabolic parameters (such as body weight, glucose homeostasis, and
blood lipids) and liver function and structure in ND group (see Supple-
mentary Fig. 2), all subsequent experimental results were thusbeticmice. (A–B)Adultmale C57BL6Jmicewere fed 12weeks of normal diet (ND) or high-
termined via high performance liquid chromatography (HPLC). (B) Leucine tolerance test
AA (ND + BCAA, HFD + BCAA) or vehicle (ND, HFD) for 12 weeks. (C) Quantiﬁcation of
(F) adipocyte size were determined. n = 8–10 per group. *P b 0.05 versus ND; #P b 0.05
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BCAA supplementation during HFD-induced obesity/diabetic condi-
tions. To clarify whether increased circulating BCAA contributes to or
protects against HF-induced metabolic disorders, the effects of BCAA
supplementation upon body weight, fat mass, and liver lipogenesis
were determined. Compared to the HFD group, the HFD + BCAA
group consumed equal water, but moderately decreased food quantity
(see Supplementary Fig. 4A and B). Moreover, BCAA supplementation
attenuated HFD-induced weight gain (Fig. 1D), decreased fat mass
(Fig. 1E), and reduced adipocyte cell diameter (Fig. 1F).
Increased hepatic de novo lipogenesis and resultant ectopic lipid de-
position contributes to liver injury in obese individuals (Donnelly et al.,
2005). Suppression of hepatic lipogenesis improves metabolic proﬁle
and insulin sensitivity (Postic and Girard, 2008). HFD caused signiﬁcant
hepatic lipid accumulation as evidenced by large lipid droplets and ele-
vated liver triglyceride (TG) content (Fig. 2A). Interestingly, BCAA sup-
plementation atop HFD signiﬁcantly reduced abundance of large
hepatic lipid droplets and liver TG content (Fig. 2A). Because sterol reg-
ulator element binding protein-1c (SREBP-1c) is themaster regulator of
hepatic lipogenic program (Neuschwander-Tetri, 2010), we next deter-
mined the effect of BACC upon HFD-induced SREBP-1c expression. As
expected, hepatic expression level of SREBP-1c [full-length SREBP-1c:
SREBP-1c (ﬂ); partial SREBP-1c: SREBP-1c (p)] was signiﬁcantly elevat-
ed in HFD mice (Fig. 2B). Consistent with prior observations (reduced
large lipid droplets and reduced hepatic TG content), BCAA supplemen-
tation signiﬁcantly inhibited SREBP-1c expression (Fig. 2B). Conse-
quently, the mRNA expression levels of SREBP-1c targeted genes
related to de novo lipogenesis, including acetyl-coA carboxylase-1
(ACC1), fatty acid synthesis (FASN), stearoyl-CoA desaturase-1
(SCD1), elongation of very long chain fatty acids protein-6 (ELOVL6),
and diacylglycerol acyltransferase-1 (DGAT1) were all suppressed by
BCAA supplementation (Fig. 2C). Taken together, these data demon-
strated BCAA blocked hepatic lipogenic responses during HFD
conditions.Fig. 2. BCAA supplementation suppressed hepatic de novo lipogenesis in HFD-induced obese/di
high-fat plus BCAA diet (HFD + BCAA), or rapamycin (RAPA, 1 mg/kg body weight intraperito
(A) Upper: HE staining in liver sections (n = 10 per group). Lower: hepatic TG content (n =
p-AKT, AKT, p-mTOR, and mTOR by Western blot (n = 6 per group). (C) Expression of hepati
(A, B, and C): *P b 0.05 versus HFD and #P b 0.05 versus HFD + BCAA. Data presented as mea
(BSA) or oleic acid (OA, 1 mM) for 12 h. Effects of BCAA (5 mM), rapamycin (RAPA, 1 μM
determined. (D) Expression of SREBP-1c (ﬂ), SREBP-1c (p), and p-AKT/AKT ratio by We
(E) Intracellular TG content, as measured via commercial kit. For (D and E): n = 4 per group. *Recent studies have demonstrated that the mammalian target of
rapamycin (mTOR) activation plays a critical role in BCAA biological
functions (Lynch and Adams, 2014). Moreover, persistent activation of
hepatic mTOR signaling reduces AKT activity, subsequently inhibiting
SREBP-1c expression and lipogenic responses under HFD conditions
(Porstmann et al., 2008; Yecies et al., 2011). To determine whether
BCAA inhibition of SREBP-1c expression and lipogenic responses in
HFD conditions is mediated by mTOR/AKT signaling, additional in vivo
and in vitro experiments were performed. In vivo BCAA supplementa-
tion signiﬁcantly increased mTOR phosphorylation and inhibited AKT
phosphorylation (Fig. 2B). Co-treatment with rapamycin (RAPA)
inhibited BCAA-induced mTOR phosphorylation, increased AKT phos-
phorylation, stimulated SREBP-1c expression (Fig. 2B), enhanced
lipogenic enzyme expression (Fig. 2C), and increased both large lipid
droplet abundance and hepatic TG content (Fig. 2A). To further deter-
mine whether the lipogenic inhibitory effect of in vivo BCAA and its in-
volved signaling mechanisms occur directly in hepatic cells, in vitro
experiments were performed in cultured primary hepatocytes isolated
from C57BL6J mice. BCAA administration signiﬁcantly blocked oleic
acid (OA)-mediated AKT activation and subsequent SREBP-1c expres-
sion, all of which were restored by rapamycin co-treatment (Fig. 2D).
Consistently, BCAA suppressed OA-induced TG accumulation, an effect
reversed by RAPA andmimicked by AKT inhibition (Fig. 2E). Collective-
ly, the experimental results presented in Figs. 1 and 2 demonstrated
BCAA reduced body weight and inhibited hepatic de novo lipogenesis
in HFD-induced obese animals, suggesting a beneﬁcial metabolic
impact.
3.2. BCAA Supplementation Caused Signiﬁcant Liver Damage in HFD Mice
Having demonstrated the systemic and hepatic metabolic effects of
BCAA supplementation, we next determined the effects of BCAA upon
HFD-induced liver injury. Compared with plasma levels of ALT
(~50 IU/L) and AST (~100 IU/L) in ND group (Supplementary Fig. 2),abeticmice viamTOR signaling. (A–C) Adult C57BL6Jmicewere fed on high-fat diet (HFD),
neal injection, every other day) atop HFD + BCAA (HFD + BCAA + RAPA) for 12 weeks.
10 per group). (B) Expression of hepatic SREBP-1c (full length, ﬂ), SREBP-1c (partial, p),
c ACC1, FASN, SCD1, ELOVL6, and DGAT1 mRNA by real-time PCR (n = 6 per group). For
n + SEM. (D–E) Cultured primary hepatocytes were treated with bovine serum albumin
), and AKT inhibitor (AKTi, 10 μM) co-treatment upon hepatocyte lipogenesis were
stern blot. Left panel: representative blots; right three panels: quantiﬁcation data.
P b 0.05. Data presented as mean + SEM.
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AST (~150 IU/L), suggesting that HFD induced lipotoxic liver damage
in mice (Fig. 3A). Somewhat to our surprise, plasma AST and ALT were
signiﬁcantly elevated when BCAA was concomitantly given atop HFD
(Fig. 3A). Hepatic inﬂammation is a hallmark of HFD-induced fatty
liver damage (Angulo, 2002). As shown in Fig. 3B, compared with HFD
group, BCAA supplementation signiﬁcantly upregulated the expression
of proinﬂammatory cytokines (TNF-α, IL-6, IL-1β, andMCP-1), strongly
demonstrating that BCAA exacerbated NAFLD-related hepatic inﬂam-
mation. Taken together, these data suggest BCAA supplementation ex-
acerbated HFD-induced liver structure/function injury, divergent from
the apparent beneﬁcial metabolic effects presented in Figs. 1 and 2.
Additional studies were conducted to identify the underlyingmech-
anisms responsible for this contradictory effect. Given that FFA-
mediated lipotoxicity is a common cause of liver damage in HFD condi-
tions, it was plausible the hepatic pathological changes observed in
BCAA supplemented mice were due to hepatic FFA accumulation and
resultant lipotoxicity. Indeed, our results demonstrated BCAA supple-
mentation signiﬁcantly increased hepatic FFA content (Fig. 3C). To fur-
ther determine how increased FFA may cause liver damage, we
determined the effect of BCAA supplementation upon lipid peroxidation
and hepatic apoptotic cell death, two well-deﬁned pathways mediating
FFA lipotoxicity (Neuschwander-Tetri, 2010). BCAA supplementation
signiﬁcantly increased lipid peroxidation, evidenced by increased
malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) (Fig. 3D).
Moreover, compared to the HFD group, the HFD+ BACC group exhibit-
ed signiﬁcantly increased hepatic apoptosis, evidenced by TUNEL stain-
ing (Fig. 3E) and cleaved caspase-3 (Fig. 3F). Taken together, these data
demonstrated BCAA supplementation atop HFD increased hepatic FFA
accumulation and lipid peroxidation, damaging liver structure and
function.
3.3. BCAA Supplementation Aggravated HFD-Induced Hyperlipidemia Due
to AMPKα2-Mediated Adipocyte Lipolysis
The above results demonstrated that, despite suppression of de novo
hepatic lipogenesis by BCAA supplementation atop HFD, hepatic FFA ac-
cumulation increases with consequent liver injury. Fig. 1 demonstrated
BCAA supplementation signiﬁcantly reduced fat mass, themajor sourceFig. 3. BCAA caused signiﬁcant liver damage in HFD mice. (A) Plasma ALT and AST were mea
cytokines mRNA levels were determined, which was compared to normal diet (dotted line),
group). (D) Hepatic MDA and 4-HNE (two common indices of lipid peroxidation, n = 8
(F) Hepatic cleaved and non-cleaved caspase-3 expression levels determined by Western blotof circulating lipids. Together, these results suggest increased hepatic
FFA accumulation is likely a consequence of increased adipose lipolysis
with resultant hyperlipidemia. To obtain direct evidence supporting this
notion, in vivo and in vitro experiments were performed. First, BCAA
supplementation signiﬁcantly aggravatedHFD-induced hyperlipidemia,
indicated by increased circulating triglycerides (TG) and FFA levels
(Fig. 4A). Second, although BCAA did not inﬂuence lipolysis induced
by CL-316243 (β3-adrenergic receptor agonist), the inhibitory effects
of insulin upon CL-316243-induced lipolysis were signiﬁcantly im-
paired in the BCAA group, as evidenced by increased FFA and glycerol
release (Fig. 4B+insulin). Third, isoprenaline (ISO) caused signiﬁcant
lipolysis in cultured adipocytes, in both the presence and absence of
BCAA (Fig. 4C, middle two bars). Insulin signiﬁcantly attenuated ISO-
induced lipolysis in control adipocytes. However, this inhibitory effect
was signiﬁcantly blunted by BCAA (Fig. 4C, last two bars). Finally,
BCAA supplementation resulted in signiﬁcant whole body insulin resis-
tance, as evidenced by increased plasma insulin levels during the glu-
cose tolerance test (GTT, Fig. 4D), attenuated the glucose-countering
effect of insulin during the insulin tolerance test (ITT, Fig. 4E), and in-
creased the HOMA-IR index (Fig. 4F). Taken together, these in vivo
and in vitro data suggest that BCAA reduced adiposity, increased FFA re-
lease, and exacerbated hyperlipidemia, potentially through blocking the
inhibitory effects of insulin on adipocyte lipolysis.
As observed in Fig. 4B/C, BCAA itself failed to affectβ-AR-induced ad-
ipocyte lipolysis in vivo and in vitro; however, BCAA signiﬁcantly pro-
moted lipolysis through reducing insulin-mediated anti-lipolytic
effects in the adipocyte. Next, we determined the molecular mecha-
nisms to explain how BCAA inﬂuenced insulin-mediated anti-lipolytic
effects in cultured adipocytes. Aswe have demonstrated BCAA inhibited
hepatic lipogenesis viamTOR activation (Fig. 2),we ﬁrst determined the
role of mTOR in BCAA-induced adipocyte lipolysis. BCAA signiﬁcantly
activated adipocyte mTOR signaling, an effect abolished by rapamycin
(Fig. 5A). However, because rapamycin failed to inhibit BCAA-
enhanced lipolysis upon insulin stimulation (Fig. 5A), BCAA likely pro-
motes adipocyte insulin resistant-lipolysis in an mTOR-independent
fashion. Recently, it was demonstrated nicotine promotes adipocyte li-
polysis via reactive oxygen species (ROS)-mediated AMP-activated pro-
tein kinase-α2 (AMPKα2) activation (Wu et al., 2015). As we have
demonstrated BCAA supplementation caused signiﬁcant superoxidesured in HFD and HFD + BCAA group (n = 10 per group). (B) Hepatic proinﬂammatory
n = 10 per group. (C) Hepatic FFA content in HFD and HFD + BCAA group (n = 6 per
per group). (E) Hepatic apoptosis determined by TUNEL staining (n = 8 per group).
(n = 6 per group). *P b 0.05 versus HFD. Data presented as mean + SEM.
Fig. 4. BCAA exacerbated HFD-induced hyperlipidemia and insulin resistance, due to aberrant lipolysis. HFD-fedmicewere given BCAA daily for 12weeks. (A) After 6 hour-fasting, plasma
TG and FFA levelswere determined. (B) In vivo lipolysis was determined in HFD andHFD+BCAA group. n= 6 per group. (C) In vitro lipolysis was performed in cultured adipocyteswith
orwithout BCAA (5mM) co-treatment for 6 h perMethods. n=6per group. (D to F) After 6 hour-fasting, glucose homeostasiswas determined inHFD andHFD+BCAAmice. (D) Glucose
tolerance test (GTT) and insulin release during GTT. (E) Insulin tolerance test (ITT). (F) HOMA-IR indexes, calculated after GTT and ITT. n = 6 per group. *P b 0.05. Data presented as
mean + SEM.
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activation (Supplementary Fig. 4D), and lipid peroxidation (Fig. 3D), we
hypothesized BCAA-enhanced adipocyte lipolysis may also involveFig. 5. AMPKα2, but not mTOR, signalingmediates BCAA-enhanced lipolysis in adipocytes. (A) C
(RAPA, 1 μM) for 6 h. Insulin (10 ng/ml) was added to culture medium for 10 min, followed by
adipocytes byWestern blot (upper panel); lipolytic ratesweremeasuredby glycerol release into
ACC inwhite adipose tissue isolated fromHFD andHFD+BCAAgroupmice (n=6 per group). (
C (CC, 10 μM) for 6 h. Insulin and ISOwere added to culturemedium as described in Fig. 5A. (C)
panel) and glycerol release in supernatant (right panel). (D) PDE activity in adipocytes (upper
and ATGL expression in adipocytes by Western blot (n = 6 per group). (F) On Day 5 after diff
AMPKα2 siRNA (siAMPKα2). 48 h after siRNA transfection, expression of AMPKα1 and AMP
were determined in siRNA-transfected adipocytes (right panel). n = 5 per group. *P b 0.05. AlAMPKα2 activation. Several in vivo and in vitro lines of evidence strong-
ly support this notion. First, in vivo BCAA supplementation atop HFD
signiﬁcantly increased phosphorylation levels of AMPK and acetyl-coAultured adipocytes were treatedwith vehicle (Veh), BCAA (5mM), or BCAA+ rapamycin
90 minute-stimulation by isoprenaline (ISO, 10 μM). Expression of p-mTOR and mTOR in
supernatant (lower panel). n=6per group. (B) Expression of p-AMPK, AMPK, p-ACC, and
C to E) Cultured adipocyteswere treatedwith vehicle (Veh), BCAA, or BCAA+Compound-
Effects of different doses of BCAAupon expression of p-AMPK and AMPK in adipocytes (left
panel) and glycerol release in supernatant (lower panel). (E) p-AMPK, AMPK, p-HSL, HSL,
erentiation, adipocytes treated by control siRNA (siCon), AMPKα1 siRNA (siAMPKα1), or
Kα2 was determined by Western blot (left two panels). Effects of BCAA upon lipolysis
l data presented as mean + SEM.
163F. Zhang et al. / EBioMedicine 13 (2016) 157–167carboxylase (ACC) in adipose tissue (Fig. 5B). Second, in cultured adipo-
cytes, insulin signiﬁcantly decreased ISO-induced AMPK activation.
BCAA addition blunted the inhibitory effects of insulin and increased
AMPK phosphorylation in a concentration-dependent manner (Fig. 5C,
representative blot and summary data in left two panels). Consequent-
ly, insulin's inhibitory effect upon ISO-induced lipolysis was reversed by
BCAA in a concentration-dependent fashion (Fig. 5C, right panel). Third,
BCAA signiﬁcantly suppressed the activity of phosphodiesterases (PDE),
a key anti-lipolytic molecule (Fig. 5D, top panel) (Chaves et al., 2011),
and signiﬁcantly increased lipolysis in cultured adipocytes (Fig. 5D, bot-
tom panel). Inhibition of AMPK by Compound-C (CC, speciﬁc AMPK in-
hibitor) signiﬁcantly attenuated the inhibitory effects of BCAA upon
PDE, and reduced BCAA-enhanced lipolysis (Fig. 5D). Fourth, to further
investigate which lipase is involved in BCAA-enhanced lipolysis, we de-
termined the expression levels of two dominant lipases in the adipo-
cyte, hormone sensitive lipase (HSL) and adipose triglyceride lipase
(ATGL) (Duncan et al., 2007). BCAA signiﬁcantly increased HSL phos-
phorylation at serine660 without altering ATGL expression level
(Fig. 5E). Inhibition of AMPK by Compound-C abolished BCAA-
enhanced HSL phosphorylation (Fig. 5E). Finally, to determine the spe-
ciﬁc AMPK subunits responsible for BCAA-induced lipolysis, cultured
adipocytes were transfected with AMPKα1 or AMPKα2 speciﬁc siRNA
(Fig. 5F, left two panels). As summarized in Fig. 5F (right panel),
BCAA-enhanced lipolysis was blocked by AMPKα2, but not AMPKα1,
knockdown. Collectively, these results demonstrated BCAA blocksFig. 6. Inhibition of lipolysis abolished BCAA-enhanced hyperglycemia andweight loss, improve
were treated with HFD, HFD+ BCAA, or HFD+ BCAA+ acipimox (10 mg/kg body weight, dai
(n= 10 per group). Lean and fat mass (middle panel), and adipocyte size (right panel) were de
(C) Glucose homeostasis (GTT, insulin release during GTT, and ITT) was evaluated (n= 6 per g
hepatic MDA and 4-HNE (n = 8 per group). (F) Hepatic apoptosis determined by TUNEL stai
presented as mean + SEM.insulin-mediated anti-lipolytic effects and subsequently enhances lipol-
ysis via AMPKα2-mediated PDE suppression and HSL activation,
resulting in increased adipocyte FFA release.3.4. Inhibition of Lipolysis Abolished BCAA-Enhanced Hyperglycemia and
Weight Loss, Improved Insulin Sensitivity, but Failed to Normalize BCAA-
Induced Liver Injury
To determinewhether increased adipocyte lipolysis and subsequent
FFA release are causatively related to BCAA-inducedweight loss, hyper-
lipidemia, insulin resistance, and liver damage, HFD+ BCAAmice were
treatedwith acipimox, a potent lipolysis inhibitor (Fuccella et al., 1980).
As summarized in Fig. 6, acipimox abolished BCAA-induced body
weight loss (A, left) and adipose reduction (A, middle), reversed adipo-
cyte size (A, right), reduced plasma TG and FFA levels to slightly below
control (B), and improvedwhole body insulin sensitivity (C). These data
support lipolysis is responsible for body weight loss, adipose reduction,
hyperlipidemia, and insulin resistance in HFD+ BCAA animals. Howev-
er, BCAA-induced liver damage was not completely blocked by
acipimox. PlasmaAST/ALT levels (Fig. 6D), hepaticMDAand 4-HNE con-
tent (Fig. 6E), and hepatic apoptotic cell death (Fig. 6F) were all signiﬁ-
cantly greater in acipimox-treated animals than HFD control animals.
These data suggest BCAAmay have direct deleterious effect upon hepat-
ic structure/function in HFD-fed mice.d insulin sensitivity, but failed to normalize BCAA-induced liver injury. Adult C57BL6Jmice
ly IP injection) for 12 weeks. (A) Left panel, body weight was monitored every two weeks
termined (n= 10 per group). (B) Quantiﬁcation of plasma TG and FFA (n= 8 per group).
roup). (D) Quantiﬁcation of plasma ALT and AST (n = 8 per group). (E) Determination of
ning (n = 8 per group). *P b 0.05 versus HFD and #P b 0.5 versus HFD + BCAA. All data
164 F. Zhang et al. / EBioMedicine 13 (2016) 157–1673.5. BCAA Inhibited Hepatic Autophagy in Response to Lipid Exposure by
mTOR Signaling Activation
Hepatic autophagy is a compensatory protective process against
FFA-induced lipotoxicity (Lin et al., 2013; González-Rodríguez et al.,
2014). Insufﬁcient autophagy results in apoptotic death (Codogno and
Meijer, 2005). We have demonstrated BCAA inhibition of hepatic lipo-
genesis is mediated by mTOR activation (Fig. 2), the master regulatory
molecule in autophagosome formation. Next, we determined if BCAA
may inhibit hepatic autophagy, contributing to hepatic apoptosis
(Fig. 3E/F) and liver injury. BCAA supplementation indeed blocked
HFD-induced autophagy activation, as evidenced by reduced light
chain 3-II (LC3-II) expression (Fig. 7A: GFP-LC3 droplets formation;
Fig. 7B: LC3-II western analysis) and increased hepatic p62 expression
(Fig. 7B). Rapamycin treatment blocked the inhibitory effect of BCAA
upon autophagy, evidenced by increased LC3-II and reduced p62 ex-
pression (Fig. 7C). Moreover, BCAA inhibited palmitate-induced au-
tophagy in cultured hepatic cells in a dose-dependent manner
(Fig. 7D), an effect reversed by rapamycin (Fig. 7E). These data demon-
strate BCAAactivatesmTOR signaling, and subsequently inhibits hepatic
autophagy in response to lipid exposure.
3.6. In Vivo mTOR Inhibition Had No Signiﬁcant Effect Upon BCAA-Induced
Plasma FFA Elevation but Signiﬁcantly Attenuated Liver Injury
The aforementioned in vitro and in vivo experimental results dem-
onstrated two separate signaling systems are activated in adipocytes
and hepatic cells, which are respectively responsible for lipolysis
(AMPKα2) and liver injury (mTOR). In a ﬁnal attempt to provide direct
evidence that inhibition of hepatic lipogenesis and autophagy by mTOR
activation contributes to BCAA-enhanced hepatic lipotoxicity and liver
injury, the effect of mTOR inhibition upon plasma FFA and liver injury
was determined. Rapamycin does not block BCAA-induced plasma FFA
elevation (Fig. 8A left panel). This result is consistent with our in vitroFig. 7. BCAA inhibited hepatic autophagy in response to lipid exposure by activating mT
HFD + BCAA + RAPA (rapamycin, 1 mg/kg body weight, IP injection every other day) for 12
p-mTOR, mTOR, LC3-I/II, and p62 protein expression were determined by Western blot fro
expression were determined by Western blot from HFD + BCAA and HFD + BCAA + RAPA g
BCAA (0, 1, 5, 10 mM) in the absence or presence of palmitate (500 μM) for 24 h. LC3-I/II prot
(n = 3 per group). (E) Cultured hepatocytes were treated with or without BCAA (5 mM) o
mTOR, and LC3-I/II were determined by Western blot (n = 3 per group). *P b 0.05. All data prresults (Fig. 4) demonstrating adipocyte lipolysis is mediated by
AMPKα2 but not mTOR. However, rapamycin treatment signiﬁcantly
attenuated BCAA-induced liver damage, as evidenced by normalized
plasma AST/ALT levels (Fig. 8B), reduced BCAA-enhanced lipid peroxi-
dation (Fig. 8C), attenuated hepatic apoptosis (Fig. 8D), and decreased
mRNA expression levels of proinﬂammatory cytokines in the liver
(Fig. 8E). In cultured hepatocytes, BCAA obviously increased FFA-
induced apoptosis, whichwas reversed by rapamycin or carbamazepine
co-treatment (Supplementary Fig. 6). Carbamazepine is an autophagy
inducing drug (Hidvegi et al., 2010; Lin et al., 2013). These in vitro
data revealed that mTOR-mediated autophagy inhibition plays a crucial
role in hepatic lipotoxicity regulated by BCAA. Interestingly, although
rapamycin failed to normalize plasma FFA concentration, hepatic FFA
accumulation was completely normalized by rapamycin (Fig. 8A, right
panel).
4. Discussion
We have made several important observations in the current study.
Firstly, we demonstrated BCAA supplementation attenuated HFD-
inducedweight gain, decreased fatmass, inhibited expression of hepatic
lipogenic enzymes, and reduced hepatic triglyceride contents. However,
BCAA reduced HFD-induced body weight at the expense of abnormal li-
polysis, resulting in hyperlipidemia, whole body insulin resistance, and
hepatic lipotoxicity. BCAA are abundant ingredients in the human diet
accounting for nearly 20% of the total protein intake (Harris et al.,
2005). It has been suggested that BCAA intake reduces body weight
gain and inhibits appetite by acting upon the central nervous system
(Hutson et al., 2005). However, our experimental results suggest in-
creased adipose lipolysis, not reduced food intake, is primarily responsi-
ble for BCAA supplementation-induced weight loss. Although BCAA
moderately reduced food intake, inhibition of lipolysis completely re-
stored fat mass and body weight in BCAA supplemented HFD mice.
Taken together, these results provide a likely explanation for theOR signaling. GFP-LC3 transgenic mice were treated with ND, HFD, HFD + BCAA, or
weeks. (A) GFP-LC3 droplets were analyzed in the liver (n = 10 per group). (B) Hepatic
m ND, HFD, and HFD + BCAA groups (n = 4 per group). (C) Hepatic LC3-I/II and p62
roups (n = 4 per group). (D) Cultured hepatocytes were treated with different doses of
ein expression was evaluated by Western blot and normalized against β-actin expression
r rapamycin (1 μM) after 24 h of palmitate (500 μM) exposure. Expression of p-mTOR,
esented as mean + SEM.
Fig. 8. In vivo mTOR inhibition had no signiﬁcant effect upon BCAA-induced plasma FFA elevation, but signiﬁcantly attenuated liver injury. Adult C57BL6J mice were treated with HFD,
HFD + BCAA, or HFD + BCAA + RAPA (rapamycin, 1 mg/kg body weight, IP injection every other day) for 12 weeks. (A) Plasma and hepatic FFA were determined. (B) Plasma ALT
and AST were determined. (C) Quantiﬁcation of hepatic MDA and 4-HNE. (D) TUNEL staining on liver sections. (E) Hepatic mRNA expression levels of inﬂammatory cytokines were
determined by real time-PCR. n = 10 per group. *P b 0.05 versus HFD group and #P b 0.05 versus HFD + BCAA group. Data presented as mean + SEM. (F) Schematic reviewing
proposed mechanism underlying BCAA-aggravated hepatic lipotoxicity. HFD induces BCAA catabolic dysfunction in mice. Under HFD conditions, increased BCAA consumption
increases circulating BCAA. BCAA-induced ROS promotes AMPK phosphorylation and AMPKα2 triggers lipolysis. BCAA-enhanced lipolysis induces hyperlipidemia. Elevated circulating
FFA results in insulin resistance and lipotoxic liver injury. Meanwhile, BCAA activate hepatic mTOR signaling, inhibit lipogenesis and autophagy, therefore increasing hepatic
susceptibility to FFA-mediated lipotoxicity. Overall, increased BCAA consumption aggravates HFD-induced hepatic lipotoxicity, providing mechanistic insight regarding diet-induced
steatohepatitis pathogenesis.
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ates weight gain, whereas increased plasma BCAA is associated with
NAFLD and liver injury.
Secondly, we have demonstrated that BCAA increased adipocyte li-
polysis and FFA release via AMPKα2-dependent HSL activation. Lipoly-
sis rates are precisely regulated through hormonal and biochemical
signals. Initiation of TG hydrolysis in adipose tissue is controlled by
two enzymes, HSL and ATGL (also known as desnutrin). HSL hydrolyses
triglycerides, diglycerides, and cholesteryl esters, although with much
greater speciﬁcity for diacylglycerol (DG). Lipolytic agents (such as β-
adrenergic agonists) acutely regulate HSL by increasing cellular cyclic
adenosine monophosphate (cAMP) levels, thus activating cAMP-
dependent protein kinase (protein kinase A, PKA). PKA phosphorylates
HSL at serine563, serine659, and serine660, thereby increasing its intrinsic
activity. PKA also promotes HSL translocation from cytosol to the lipid
droplet (Yeaman, 2004). Activation of phosphodiesterase (PDE) reduces
cAMP levels, with consequent reduced PKA activity, inhibiting HSL
phosphorylation and translocation. In contrast to HSL, the activity of
ATGL is speciﬁc for TG and has limited activity against DG. Our current
study demonstrated BCAA supplementation had no signiﬁcant effect
on ATGL expression. However, BCAA supplementation signiﬁcantly re-
duced PDE activity and increased HSL phosphorylation without altering
its expression. These results suggest BCAA increases adipocyte lipolysis
likely via attenuating PDE-inhibition of HSL.
AMPK is a crucial sensor of redox status and energy balance. Its role
in lipolysis is controversial. Initial evidence of a regulatory role for AMPK
in adipocyte lipolysis originated from the in vitro observation thatHSL is
phosphorylated by AMPK at serine565. Phosphorylation at serine565
blocks the phosphorylation of HSL by PKA at serine563, 659, 660
(Yeaman, 2004). Based upon these in vitro studies, it was proposed
AMPKactivationwould exert an anti-lipolytic effect in adipocytes. How-
ever, several recent studies have demonstrated AMPK activation pro-
motes lipolysis (Yin et al., 2003; Koh et al., 2007), supported by
evidence acute and chronic exercise increase catecholamine release, li-
polysis, and AMPK activation in the adipose tissue (Koh et al., 2007).
An anti-lipolytic role for AMPK appears counterintuitive because duringexercise, circulating levels of FFA are increased signiﬁcantly. Such con-
tradictory results may be explained by the opposite regulatory effects
exerted by different AMPK isoforms. Speciﬁcally, adipocytes from
AMPKα1-knockout mice exhibit increased lipolysis, indicating an anti-
lipolytic role of this enzyme (Daval et al., 2005). In contrast,mice lacking
the AMPKα2 subunit manifest increased adiposity and weight gain
(Villena et al., 2004), suggesting a pro-lipolytic role of this subunit.
More importantly, a recent study demonstrated nicotine-induced lipol-
ysis is lost in AMPKα2, but not AMPKα1, knockout adipocytes, further
supporting the role of AMPKα2 in promoting lipolysis (Wu et al.,
2015). To this end, our current study demonstrated BCAA signiﬁcantly
increased adipocyte lipolysis, an effect blocked by AMPKα2, not
AMPKα1, knockdown. However, the detailed molecular signaling by
which BCAA inhibits PDE activity via AMPKα2 remains unidentiﬁed.
Moreover, whether BCAA-induced HSL phosphorylation is a direct re-
sult of AMPKα2, or an indirect effect via PDE inhibition,was not directly
addressed in this study. These important questions warrant additional
ongoing investigation, underway in our laboratory.
Thirdly, we have provided the direct evidence that BCAA supple-
mentation atop HFD caused signiﬁcant liver damage via two mTOR-
activated signaling pathways: inhibition of hepatic lipogenesis and
blockage of autophagy. De novo hepatic lipogenesis is regulated by a
group of genes controlled by SREBP-1c, the master regulator of the he-
patic lipogenic program, regarded as a therapeutic target against hepat-
ic lipogenesis and its resultant metabolic disorders (Postic and Girard,
2008). Our current study demonstrated BCAA supplementation signiﬁ-
cantly inhibited hepatic SREBP-1c expression and reduced lipogenesis
enzyme expression in an mTOR-dependent manner. However, mTOR
blockade with rapamycin signiﬁcantly attenuated, not exacerbated,
BCAA-induced liver injury. These results suggest the beneﬁcial effect
of mTOR-mediated global inhibition of hepatic lipogenesis by BCAA is
overwhelmed by stronger deleterious signaling pathways concurrently
activated by mTOR.
Although de novo hepatic lipogenesis contribute to liver FFA abun-
dance, circulating FFA represent greater pools for hepatic FFA accumula-
tion. Under physiologic conditions, intrahepatic FFA can be re-esteriﬁed
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studies demonstrated converting FFA to TG is critical in protecting the
liver from FFA-induced lipotoxicity. Clinical observations reveal patients
with advanced steatohepatitis express signiﬁcantly reduced key hepatic
lipogenic enzymes, and have increased hepatic FFA and signiﬁcantly re-
duced hepatic TG (Nagaya et al., 2010; vander Poorten et al., 2013). Spe-
ciﬁcally, genetic interruption of hepatic TG synthesis leads to increased
hepatic FFA accumulation, inﬂammation, ﬁbrosis, and exacerbated liver
damage (Yamaguchi et al., 2007). These results suggest that although
global inhibition of hepatic de novo lipogenesis is metabolically beneﬁ-
cial, inhibition of hepatic FFA-TG conversion under hyperlipidemic con-
ditions will be injurious to the liver. Our current study demonstrated
that BCAA not only globally inhibited hepatic lipogenesis, but also stim-
ulated adipocyte lipolysis, increasing circulating FFA. Unfortunately, FFA
accumulated in hepatic cells cannot be re-esteriﬁed and stored as TG,
because DGAT1 (a key enzyme for TG synthesis from FFA) is inhibited
by BCAA (Fig. 2C). FFA-mediated hepatic lipotoxicity is thus intensiﬁed.
Our results support this conclusion: although in vivo inhibition ofmTOR
failed to reduce BCAA-induced hyperlipidemia, BCAA-induced liver in-
jury was attenuated.
Autophagy is a pivotal self-repair mechanism maintaining intracel-
lular homeostasis via degradation of injured organelles and misfolded
proteins in response to stress. Insufﬁcient autophagy activates apoptosis
signaling, resulting in cell death (Codogno and Meijer, 2005). In non-
alcoholic fatty liver, hepatic autophagy is impaired due to mTOR activa-
tion. Restoring autophagy by rapamycin or carbamazepine treatment
ameliorates disease severity (Lin et al., 2013). Furthermore, autophagy
activation protects against FFA-mediated lipotoxicity both in vivo and
in vitro (Lin et al., 2013; González-Rodríguez et al., 2014). In this
study, we demonstrated BCAA activated mTOR and signiﬁcantly
inhibited hepatic autophagy in response to lipid exposure, resulting in
hepatic apoptosis. Blockade of mTOR signaling by rapamycin restored
hepatic autophagy response, attenuated FFA-induced lipotoxicity, and
reduced hepatic apoptosis.
In summary, our results demonstrated BCAA causes hepatic injury
via complex mechanisms involving both adipocytes and hepatic cells.
In adipocytes, BCAA activates AMPKα2 and stimulates lipolysis, increas-
ingplasma FFA,which in turn results in hepatic FFA accumulation. In the
liver, BCAA activatesmTOR,which inhibits FFA to TG conversion and au-
tophagy. Inhibition of hepatic FFA to TG conversion blocks the hepatic
FFA outﬂow route, intensifying FFA lipotoxicity. Blockade of autophagy
impedes the self-repairing mechanism protective against lipotoxicity,
increasing apoptotic cell death. There exist many similarities between
BCAA-induced (as demonstrated in this study) and nicotine-induced
(recently reported by Zou and colleagues) metabolic alterations (Wu
et al., 2015). However, BCAA-induced liver injury is far worse than
that caused by nicotine. Lipolysis inhibition completely normalized the
liver structure and function in nicotine-treated, but not BCAA-treated,
animals due to the directly hepatocyte toxic effects of BCAA. As BCAA
are abundant in protein, our results call for caution regarding the inges-
tion of high protein diets in obesity and diabetic individuals, unless their
BCAA metabolic pathways are determined normal. Moreover, our re-
sults call to attention that high fat is not the only harmful factor in the
western meat-rich diet. The combination of high fat and high protein
consumption may generate further dangerous metabolic disorders and
organ injury.
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